You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMinoxidil
Accession NumberDB00350  (APRD00086, DB08225)
TypeSmall Molecule
GroupsApproved
DescriptionA potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
Structure
Thumb
Synonyms
2,4-Diamino-6-piperidinopyrimidine 3-oxide
6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide
Alostil
Apo-gain
Loniten
Lonolox
Minossidile
Minoxidil
Minoxidilum
Minoximen
Normoxidil
Regaine
Rogaine
Tricoxidil
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Loniten 10mgTablet10 mgOralPfizer1980-12-31Not applicableCanada
Loniten 2.5mgTablet2.5 mgOralPfizer1980-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MinoxidilTablet10 mg/1OralMutual Pharmaceutical1995-12-14Not applicableUs
MinoxidilTablet2.5 mg/1OralPar Pharmaceutical1988-11-14Not applicableUs
MinoxidilTablet2.5 mg/1OralWatson Pharmaceuticals2009-10-26Not applicableUs
MinoxidilTablet2.5 mg/1OralAmerincan Health Packaging2007-07-30Not applicableUs
MinoxidilTablet10 mg/1OralA S Medication Solutions1988-11-14Not applicableUs
MinoxidilTablet10 mg/1OralCarilion Materials Management2009-10-26Not applicableUs
MinoxidilTablet10 mg/1OralRemedy Repack2013-02-262016-12-14Us
MinoxidilTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
MinoxidilTablet10 mg/1OralPar Pharmaceutical1988-11-14Not applicableUs
MinoxidilTablet10 mg/1OralWatson Pharmaceuticals2009-10-26Not applicableUs
MinoxidilTablet10 mg/1OralAmerincan Health Packaging2007-07-30Not applicableUs
MinoxidilTablet2.5 mg/1OralPhysicians Total Care, Inc.2002-10-16Not applicableUs
MinoxidilTablet2.5 mg/1OralAv Kare, Inc.2013-08-01Not applicableUs
MinoxidilTablet10 mg/1OralRemedy Repack2013-03-20Not applicableUs
MinoxidilTablet2.5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
MinoxidilTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-11-14Not applicableUs
MinoxidilTablet2.5 mg/1OralAvera Mc Kennan Hospital2015-08-21Not applicableUs
MinoxidilTablet10 mg/1OralPhysicians Total Care, Inc.1996-09-13Not applicableUs
MinoxidilTablet10 mg/1OralAv Kare, Inc.2013-08-01Not applicableUs
MinoxidilTablet2.5 mg/1OralMutual Pharmaceutical1995-12-14Not applicableUs
MinoxidilTablet10 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
MinoxidilTablet2.5 mg/1OralRemedy Repack2011-05-18Not applicableUs
MinoxidilTablet2.5 mg/1OralCarilion Materials Management1995-12-14Not applicableUs
MinoxidilTablet2.5 mg/1OralCardinal Health2007-07-30Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-gain Liq 20mg/mlLiquid20 mgTopicalApotex Corporation1992-12-31Not applicableCanada
Boost Regrowth for WomenLiquid2 g/100mLTopicalSHELBY PROFESSIONAL, INC.2012-03-01Not applicableUs
Bosley Professional Strength Hair Regrowth Treatment Regular Strength for MenLiquid50 mg/mLTopicalPuresource Inc.2013-08-15Not applicableUs
Bosley Professional Strength Hair Regrowth Treatment Regular Strength for WomenLiquid20 mg/mLTopicalPuresource Inc.2013-08-15Not applicableUs
Careone Hair Regrowth TreatmentAerosol, foam5 g/100gTopicalAmerican Sales Company2012-07-27Not applicableUs
Careone Hair Regrowth Treatment Extra StrengthSolution3 g/60mLTopicalAmerican Sales Company2009-12-15Not applicableUs
Cerafill RetaliateSolution20 mg/mLTopicalL'oreal2014-04-28Not applicableUs
Cerafill Retaliate Extra Strength for MenSolution50 mg/mLTopicalL'oreal2014-04-28Not applicableUs
Daylogic for MenAerosol, foam5 g/100gTopicalRite Aid2016-08-05Not applicableUs
Equaline Hair Regrowth Treatment for MenSolution3 g/60mLTopicalSupervalu2009-12-04Not applicableUs
Equaline Hair Regrowth Treatment for MenAerosol, foam5 g/100gTopicalSupervalu2012-03-13Not applicableUs
Equaline Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalSupervalu2011-04-17Not applicableUs
Equaline Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalSupervalu2007-03-11Not applicableUs
Equate Hair Regrowth TreatmentAerosol, foam5 g/100gTopicalWalmart Stores2012-03-01Not applicableUs
Equate Hair Regrowth Treatment for MenSolution3 g/60mLTopicalWalmart Stores2011-02-01Not applicableUs
Equate Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalWalmart Stores2011-01-27Not applicableUs
Gen-minoxidil Liq 2%Liquid2 %TopicalGenpharm Ulc1994-12-312009-08-05Canada
Good Neighbor Pharmacy Hair Regrowth Treatment for MenAerosol, foam5 g/100gTopicalAmerisource Bergen2012-03-02Not applicableUs
Good Sense Hair Regrowth TreatmentAerosol, foam5 g/100gTopicalL. Perrigo Company2012-03-01Not applicableUs
Good Sense Hair Regrowth Treatment for MenSolution3 g/60mLTopicalL. Perrigo Company2010-02-10Not applicableUs
Good Sense Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalL. Perrigo Company2012-02-11Not applicableUs
Good Sense Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalL. Perrigo Company2010-02-11Not applicableUs
Hair RegrowSolution50 mg/mLTopicalBentley Laboratories, LLC2004-08-24Not applicableUs
Hair Regrowth FormulaSolution20 mgTopicalVita Health Products Inc2011-04-15Not applicableCanada
Hair Regrowth TreatmentSolution2 %TopicalApotex CorporationNot applicableNot applicableCanada
Hair Regrowth TreatmentSolution3 g/60mLTopicalSafeway2013-11-30Not applicableUs
Hair Regrowth TreatmentSolution2 %TopicalVita Health Products Inc2001-01-162012-07-04Canada
Hair Regrowth TreatmentSolution2 g/100mLTopicalActavis Mid Atlantic LLC,2000-01-01Not applicableUs
Hair Regrowth TreatmentAerosol, foam5 g/100gTopicalMeijer Distribution2012-03-19Not applicableUs
Hair Regrowth Treatment Extra Strength for MenSolution3 g/60mLTopicalSafeway2009-12-10Not applicableUs
Hair Regrowth Treatment Extra Strength for MenSolution3 g/60mLTopicalMeijer Distribution2009-12-29Not applicableUs
Hair Regrowth Treatment Extra Strength for MenSolution3 g/60mLTopicalKroger2009-12-05Not applicableUs
Hair Regrowth Treatment for MenSolution2 g/100mLTopicalCvs Health1991-09-04Not applicableUs
Hair Regrowth Treatment for MenAerosol, foam5 g/100gTopicalCvs Health2012-03-02Not applicableUs
Hair Regrowth Treatment for MenAerosol, foam5 g/100gTopicalKroger2012-04-10Not applicableUs
Hair Regrowth Treatment for MenSolution3 g/60mLTopicalCvs Health2010-01-05Not applicableUs
Hair Regrowth Treatment for MenSolution50 mg/mLTopicalActavis Mid Atlantic LLC,2000-11-17Not applicableUs
Hair Regrowth Treatment for MenSolution5 g/100mLTopicalCvs Health2005-07-18Not applicableUs
Hair Regrowth Treatment for MenAerosol, foam5 g/100gTopicalSafeway2012-05-11Not applicableUs
Hair Regrowth Treatment for Men Extra StrengthSolution50 mg/mLTopicalRite Aid2005-11-01Not applicableUs
Hair Regrowth Treatment for Men Extra StrengthSolution50 mg/mLTopicalArmy + Air Force Exchange Service2007-05-17Not applicableUs
Hair Regrowth Treatment for Men Extra StrengthSolution50 mg/mLTopicalWalmart Stores2002-05-02Not applicableUs
Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalCvs Health2006-09-08Not applicableUs
Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalMeijer Distribution2011-04-07Not applicableUs
Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalKroger2011-02-05Not applicableUs
Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalCvs Health1990-04-15Not applicableUs
Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalRite Aid2003-01-01Not applicableUs
Hair Regrowth Treatment for WomenSolution20 mg/mLTopicalWalmart Stores2004-02-04Not applicableUs
Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalMeijer Distribution2007-12-19Not applicableUs
Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalChain Drug Consortium2000-01-01Not applicableUs
HairgroSolution2 %TopicalVita Health Products Inc2000-11-022005-07-20Canada
Harmon Face Values MinoxidilSolution2 g/100mLTopicalHarmon Stores2011-12-18Not applicableUs
Harmon Face Values MinoxidilSolution3 g/60mLTopicalHarmon Stores2011-12-18Not applicableUs
Harmon Face Values Minoxidil MensAerosol, foam5 g/100gTopicalHarmon Stores2015-07-14Not applicableUs
Image Essentials Hair Regrowth TreatmentSolution3 g/60mLTopicalKmart Corporation2011-07-12Not applicableUs
Image Essentials Hair Regrowth TreatmentSolution2 g/100mLTopicalKmart Corporation2011-06-20Not applicableUs
Image Essentials Hair Regrowth Treatment for MenAerosol, foam5 g/100gTopicalKmart Corporation2012-07-16Not applicableUs
Keranique for Women Hair Regrowth TreatmentLiquid20 mg/mLTopicalPuresource Inc.2014-02-06Not applicableUs
Kirkland Signature MinoxidilSolution5 g/100mLTopicalCostco Wholesale2013-08-25Not applicableUs
Kirkland Signature MinoxidilSolution3 g/60mLTopicalCostco Wholesale2012-05-22Not applicableUs
Kirkland Signature MinoxidilAerosol, foam5 g/100gTopicalCostco Wholesale2012-04-17Not applicableUs
Leader Hair Regrowth TreatmentAerosol, foam5 g/100gTopicalCardinal Health2012-03-16Not applicableUs
Loesch Hair Regrowth Formula Unscented Topical Solution Extra-strength for MenSolution3 g/60mLTopicalLoesch Laboratory Consultants, Inc.2014-07-30Not applicableUs
Loesch Hair Regrowth Formula Unscented Topical Solution Regular-strength for Men and WomenSolution2 g/100mLTopicalLoesch Laboratory Consultants, Inc.2014-08-11Not applicableUs
Members Mark MinoxidilAerosol, foam5 g/100gTopicalSam's West, Inc2015-09-24Not applicableUs
Members Mark MinoxidilSolution3 g/60mLTopicalSam's West, Inc2009-11-10Not applicableUs
Mens AlopexySolution50 mg/mLTopicalGenesis2016-08-08Not applicableUs
Mens Comback Hair Regrowth Treatment Extra Strength UnscentedLiquid50 mg/mLTopicalCombback International LLC2013-06-062016-01-07Us
Mens Hair Regrowth Treatment Extra StrengthSolution50 mg/mLTopicalCvs Health2000-08-01Not applicableUs
Mens Kirkland Extra StrengthSolution50 mg/mLTopicalCostco Wholesale2010-07-16Not applicableUs
Mens Rogaine Extra StrengthSolution50 mg/mLTopicalJohnson & Johnson2010-07-16Not applicableUs
Mens Rogaine Extra Strength UnscentedSolution50 mg/mLTopicalJohnson & Johnson2010-07-16Not applicableUs
Mens Rogaine Minoxidil - Unscented FormulaAerosol, foam50 mg/gTopicalJohnson & Johnson2010-10-01Not applicableUs
Mens Rogaine Unscented FormulaAerosol, foam50 mg/gTopicalJohnson & Johnson Healthcare Products, Division Of Mc Neil Ppc, Inc.2010-10-012016-03-29Us
Minox - Liq Top 20mg/mlSolution20 mgTopicalLaboratoire Riva Inc1997-08-27Not applicableCanada
MinoxidilSolution2 g/100mLTopicalWalgreen2006-09-14Not applicableUs
MinoxidilAerosol, foam5 g/100gTopicalCvs Health2014-04-29Not applicableUs
MinoxidilSolution2 g/100mLTopicalH.E.B.2011-04-04Not applicableUs
MinoxidilSolution2 g/100mLTopicalHi Tech Pharmacal Co., Inc.1996-12-24Not applicableUs
MinoxidilAerosol, foam5 g/100gTopicalH.E.B.2012-03-01Not applicableUs
MinoxidilSolution2 g/100mLTopicalWalgreen2011-02-25Not applicableUs
MinoxidilSolution3 g/60mLTopicalCvs Health2014-10-07Not applicableUs
MinoxidilSolution3 g/60mLTopicalRite Aid2016-08-18Not applicableUs
MinoxidilSolution2 g/100mLTopicalRite Aid2016-10-14Not applicableUs
MinoxidilAerosol, foam5 g/100gTopicalWalgreen2012-03-01Not applicableUs
MinoxidilSolution3 g/60mLTopicalPublix Supermarkets, Inc.2010-10-25Not applicableUs
MinoxidilSolution2 g/100mLTopicalPhysicians Total Care, Inc.1996-06-04Not applicableUs
Minoxidil FoamAerosol, foam5 g/100gTopicalPublix Supermarkets, Inc.2013-06-17Not applicableUs
Minoxidil for MenSolution3 g/60mLTopicalWalgreen2009-11-13Not applicableUs
Minoxidil for MenSolution3 g/60mLTopicalH.E.B.2010-02-16Not applicableUs
Minoxidil for WomenSolution2 g/100mLTopicalWalgreen2011-02-28Not applicableUs
Minoxidil for WomenSolution2 g/100mLTopicalCvs Health2003-01-01Not applicableUs
Minoxidil for WomenSolution2 g/100mLTopicalPublix Supermarkets, Inc.2011-04-04Not applicableUs
Minoxidil Form Men Extra StrengthSolution50 mg/mLTopicalChain Drug Consortium2003-09-11Not applicableUs
Minoxidil Regular StrengthSolution2 g/100mLTopicalH.E.B.2006-11-09Not applicableUs
Minoxidil Regular StrengthSolution2 g/100mLTopicalH.E.B.2011-05-06Not applicableUs
Minoxigaine Topical Solution - 2%Solution20 mgTopicalAltimed Pharma Inc.1995-12-311999-09-17Canada
Nioxin Hair Regrowth Treatment Extra Strength for MenSolution5 g/100mLTopicalThe Wella Corporation2014-11-01Not applicableUs
Nioxin Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalThe Wella Corporation2014-11-01Not applicableUs
Nutrastim Hair Regrowth Treatment for WomenSolution20 mg/mLTopicalVbbeauty Inc.2016-04-06Not applicableUs
Nutrastim Hair Regrowth Treatment Unscented for MenSolution50 mg/mLTopicalVbbeauty Inc.2016-04-06Not applicableUs
Pantene Pro-V Expert Collection Hair Regrowth Treatment for WomenLiquid2 g/100mLTopicalProcter And Gamble2013-11-15Not applicableUs
Qilib Hair Regrowth Treatment for MenSolution5 g/100mLTopicalGalderma2015-12-01Not applicableUs
Qilib Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalGalderma2015-12-01Not applicableUs
Re-groSolution2 g/100mLTopicalEmpress Hair Products, Ltd.2014-04-01Not applicableUs
Renewal for MenAerosol, foam5 g/100gTopicalRite Aid2012-03-14Not applicableUs
Rogaine Foam 5%Aerosol, foam5 %TopicalJohnson & Johnson2012-11-19Not applicableCanada
Rogaine Minoxidil Topical 2% SolutionSolution20 mgTopicalJohnson & Johnson1986-12-31Not applicableCanada
Signature Care Hair Regrowth TreatmentSolution3 g/60mLTopicalSafeway2015-09-04Not applicableUs
Signature Care Hair Regrowth Treatment for MenAerosol, foam5 g/100gTopicalSafeway2015-09-04Not applicableUs
Simply Right MinoxidilAerosol, foam5 g/100gTopicalSam's West, Inc2012-03-01Not applicableUs
Simply Right Minoxidil Extra StrengthSolution3 g/60mLTopicalSam's West, Inc2011-06-30Not applicableUs
SolutionSolution.02 g/mLTopicalWalgreens2014-08-08Not applicableUs
Toppik Mens Hair Regrowth Treatment Extra StrengthSolution50 mg/mLTopicalSpencer Forrest, Inc.2014-01-01Not applicableUs
Toppik Womens Hair Regrowth TreatmentSolution20 mg/mLTopicalSpencer Forrest, Inc.2014-01-01Not applicableUs
Up and Up Hair Regrowth Treatment for MenSolution5 g/100mLTopicalTarget Corporation.2015-07-29Not applicableUs
Up and Up Hair Regrowth Treatment for MenAerosol, foam5 g/100gTopicalTarget Corporation.2015-08-14Not applicableUs
Up and Up Hair Regrowth Treatment for WomenSolution2 g/100mLTopicalTarget Corporation.2015-08-31Not applicableUs
Up and Up MinoxidilAerosol, foam5 g/100gTopicalTarget Corporation.2012-03-01Not applicableUs
Up and Up MinoxidilSolution5 g/100mLTopicalTarget Corporation.2009-05-20Not applicableUs
Up and Up MinoxidilSolution2 g/100mLTopicalTarget Corporation.2009-05-27Not applicableUs
Vanarex Hair Regrowth TreatmentSolution3 g/60mLTopicalManchester Pharmaceuticals2011-02-01Not applicableUs
Women's Rogaine Foam 5%Aerosol, foam5 %TopicalJohnson & Johnson2015-03-16Not applicableCanada
Womens AlopexySolution20 mg/mLTopicalGenesis2016-08-08Not applicableUs
Womens Rogaine - UnscentedSolution20 mg/mLTopicalJohnson & Johnson2010-08-012018-12-01Us
Womens Rogaine UnscentedAerosol, foam50 mg/gTopicalJohnson & Johnson2014-09-22Not applicableUs
Womens Rogaine UnscentedSolution20 mg/mLTopicalJohnson & Johnson2010-08-01Not applicableUs
Womens Rogaine UnscentedAerosol, foam50 mg/gTopicalJohnson & Johnson2011-04-01Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
AlostilMcNeil
Apo-GainApotex
AvogainNot Available
LipogaineNot Available
LonitenPfizer
LonoloxPfizer
MinodylNot Available
MinoxigaineNot Available
MinoximenMenarini
MintopDr. Reddy's
RegaineMcNeil
RogaineJohnson & Johnson
TheroxidilEi
TricoxidilNot Available
VanarexNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5965120SH1
CAS number38304-91-5
WeightAverage: 209.2483
Monoisotopic: 209.127660127
Chemical FormulaC9H15N5O
InChI KeyZFMITUMMTDLWHR-UHFFFAOYSA-N
InChI
InChI=1S/C9H15N5O/c10-7-6-8(12-9(11)14(7)15)13-4-2-1-3-5-13/h6H,1-5,10H2,(H2,11,12)
IUPAC Name
2,6-diamino-4-(piperidin-1-yl)pyrimidin-1-ium-1-olate
SMILES
NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1
Pharmacology
IndicationFor the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.
Structured Indications
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCoughing1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
1, 2CompletedTreatmentAndrogenetic Alopecia1
2CompletedTreatmentAlopecia / Androgenetic Alopecia / Baldness1
2CompletedTreatmentAlopecia / Baldness1
2CompletedTreatmentAndrogenetic Alopecia1
2CompletedTreatmentWilliams Beuren Syndrome1
2RecruitingTreatmentFemale Pattern Hair Loss1
3Active Not RecruitingTreatmentFemale Pattern Alopecia1
3CompletedTreatmentAlopecia1
3CompletedTreatmentAndrogenetic Alopecia / Female Pattern Hair Loss1
4Not Yet RecruitingTreatmentFemale Androgenetic Alopecia1
Not AvailableCompletedBasic ScienceAndrogenetic Alopecia1
Not AvailableTerminatedTreatmentTreatment Induced Hypertension1
PharmacodynamicsMinoxidil is an orally effective direct acting peripheral vasodilator that reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. Minoxidil is also used topically to treat androgenetic alopecia. Microcirculatory blood flow in animals is enhanced or maintained in all systemic vascular beds. In man, forearm and renal vascular resistance decline; forearm blood flow increases while renal blood flow and glomerular filtration rate are preserved. The predominant site of minoxidil action is arterial. Venodilation does not occur with minoxidil; thus, postural hypotension is unusual with its administration. The antihypertensive activity of minoxidil is due to its sulphate metabolite, minoxidil sulfate.
Mechanism of actionMinoxidil is thought to promote the survival of human dermal papillary cells (DPCs) or hair cells by activating both extracellular signal-regulated kinase (ERK) and Akt and by preventing cell death by increasing the ratio of BCl-2/Bax. Minoxidil may stimulate the growth of human hairs by prolonging anagen through these proliferative and anti-apoptotic effects on DPCs. Minoxidil, when used as a vasodilator, acts by opening adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells. This vasodilation may also improve the viability of hair cells or hair follicles.
TargetKindPharmacological actionActionsOrganismUniProt ID
ATP-sensitive inward rectifier potassium channel 1Proteinyes
inducer
HumanP48048 details
Prostaglandin G/H synthase 1Proteinunknown
inducer
HumanP23219 details
Related Articles
AbsorptionMinoxidil is at least 90% absorbed from the GI tract in experimental animals and man.
Volume of distributionNot Available
Protein bindingMinoxidil does not bind to plasma proteins.
Metabolism

Approximately 90% of the administered drug is metabolized, predominantly by conjugation with glucuronic acid at the N-oxide position in the pyrimidine ring, but also by conversion to more polar products. Known metabolites exert much less pharmacologic effect than minoxidil itself.

Route of eliminationNot Available
Half life4.2 hours
ClearanceNot Available
ToxicityOral LD50 in rats has ranged from 1321-3492 mg/kg; in mice, 2456-2648 mg/kg. Side effects include cardiovascular effects associated with hypotension such as sudden weight gain, rapid heart beat, faintness or dizziness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Minoxidil.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Minoxidil.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Minoxidil.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Minoxidil is combined with Aliskiren.Approved, Investigational
AlprenololMinoxidil may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanMinoxidil may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineMinoxidil may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Minoxidil.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Minoxidil is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Minoxidil is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Minoxidil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Arsenic trioxide.Approved, Investigational
AtazanavirThe serum concentration of Minoxidil can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Minoxidil.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Minoxidil.Experimental
BarbitalBarbital may increase the hypotensive activities of Minoxidil.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Minoxidil.Withdrawn
BepridilMinoxidil may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Minoxidil.Approved
BethanidineBethanidine may increase the hypotensive activities of Minoxidil.Approved
BimatoprostMinoxidil may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bortezomib.Approved, Investigational
BosentanMinoxidil may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Minoxidil.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bupivacaine.Approved, Investigational
BupranololMinoxidil may increase the hypotensive activities of Bupranolol.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Minoxidil is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Minoxidil is combined with Candesartan.Approved
CandoxatrilMinoxidil may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Minoxidil is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Minoxidil.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Minoxidil is combined with Carvedilol.Approved, Investigational
CeliprololMinoxidil may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Minoxidil.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clonidine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Minoxidil is combined with Conivaptan.Approved, Investigational
CryptenamineMinoxidil may increase the hypotensive activities of Cryptenamine.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Minoxidil.Approved, Investigational, Vet Approved
CyclothiazideMinoxidil may increase the hypotensive activities of Cyclothiazide.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Minoxidil.Investigational
DebrisoquinMinoxidil may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineMinoxidil may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Minoxidil.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Diclofenamide.Approved
DihydralazineMinoxidil may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Minoxidil.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dipyridamole.Approved
DorzolamideMinoxidil may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Minoxidil is combined with Doxazosin.Approved
DuloxetineMinoxidil may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineMinoxidil may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Minoxidil is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Enalapril.Approved, Vet Approved
EnalaprilatMinoxidil may increase the hypotensive activities of Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Eplerenone.Approved
EpoprostenolMinoxidil may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Minoxidil is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Minoxidil.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid.Approved
FelodipineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Felodipine.Approved, Investigational
FenoldopamMinoxidil may increase the hypotensive activities of Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Minoxidil is combined with Fimasartan.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Minoxidil.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Furosemide.Approved, Vet Approved
GuanabenzMinoxidil may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Minoxidil.Approved
GuanethidineMinoxidil may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Halothane.Approved, Vet Approved
HexamethoniumMinoxidil may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Minoxidil.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Minoxidil.Approved
HydralazineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideMinoxidil may increase the hypotensive activities of Hydroflumethiazide.Approved
IloprostIloprost may increase the hypotensive activities of Minoxidil.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Indapamide.Approved
IndenololMinoxidil may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminMinoxidil may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Minoxidil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Minoxidil.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Minoxidil is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Minoxidil.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Minoxidil is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Minoxidil is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Minoxidil.Approved
KetanserinMinoxidil may increase the hypotensive activities of Ketanserin.Investigational
LabetalolThe risk or severity of adverse effects can be increased when Minoxidil is combined with Labetalol.Approved
LacidipineMinoxidil may increase the hypotensive activities of Lacidipine.Approved
LatanoprostMinoxidil may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineMinoxidil may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Levobupivacaine.Approved
LevodopaMinoxidil may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Minoxidil is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Lisinopril.Approved, Investigational
LofexidineMinoxidil may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Minoxidil is combined with Losartan.Approved
MacitentanMinoxidil may increase the hypotensive activities of Macitentan.Approved
ManidipineMinoxidil may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Minoxidil is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Minoxidil.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Mecamylamine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Minoxidil.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Minoxidil.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Minoxidil is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Minoxidil.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Minoxidil.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Minoxidil.Approved
MetipranololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Minoxidil.Approved, Investigational
MetyrosineMinoxidil may increase the hypotensive activities of Metyrosine.Approved
MibefradilMinoxidil may increase the hypotensive activities of Mibefradil.Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Minoxidil.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Minoxidil.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Minoxidil.Approved
MorphineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Morphine.Approved, Investigational
MoxonidineMinoxidil may increase the hypotensive activities of Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nadolol.Approved
NaftopidilMinoxidil may increase the hypotensive activities of Naftopidil.Investigational
NebivololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Minoxidil.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Minoxidil.Approved
NifedipineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nifedipine.Approved
NiguldipineMinoxidil may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMinoxidil may increase the hypotensive activities of Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nisoldipine.Approved
NitrendipineMinoxidil may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Minoxidil.Approved
ObinutuzumabMinoxidil may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Minoxidil.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Minoxidil.Approved, Investigational
OmapatrilatMinoxidil may increase the hypotensive activities of Omapatrilat.Investigational
OxprenololMinoxidil may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Minoxidil is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Minoxidil.Approved
PenbutololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Minoxidil.Approved, Vet Approved
PentoliniumMinoxidil may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Minoxidil.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Minoxidil.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Minoxidil.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Minoxidil.Approved
PhenoxybenzamineMinoxidil may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Minoxidil.Withdrawn
PhentolamineMinoxidil may increase the hypotensive activities of Phentolamine.Approved
PinacidilMinoxidil may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Minoxidil.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Minoxidil.Withdrawn
PolythiazideMinoxidil may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Minoxidil is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Minoxidil is combined with Prazosin.Approved
PrimidonePrimidone may increase the hypotensive activities of Minoxidil.Approved, Vet Approved
ProbenecidThe serum concentration of Minoxidil can be increased when it is combined with Probenecid.Approved
PropofolThe risk or severity of adverse effects can be increased when Minoxidil is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Propranolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Minoxidil.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Minoxidil.Approved
RasagilineRasagiline may increase the hypotensive activities of Minoxidil.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Minoxidil.Approved
RescinnamineMinoxidil may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Minoxidil.Approved
RilmenidineMinoxidil may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Minoxidil is combined with Riociguat.Approved
RisperidoneMinoxidil may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabMinoxidil may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Minoxidil is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Minoxidil.Withdrawn
SaprisartanMinoxidil may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Minoxidil.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Minoxidil.Approved, Investigational, Vet Approved
SelexipagMinoxidil may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Minoxidil.Approved, Investigational
SitaxentanMinoxidil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Minoxidil is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Minoxidil is combined with Sotalol.Approved
SpiraprilMinoxidil may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Minoxidil is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Sufentanil.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Minoxidil.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Minoxidil is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Minoxidil is combined with Telmisartan.Approved, Investigational
TemocaprilMinoxidil may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Minoxidil is combined with Terazosin.Approved
TerlipressinMinoxidil may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Minoxidil is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Minoxidil.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Minoxidil.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Thioridazine.Approved
TiboloneMinoxidil may increase the hypotensive activities of Tibolone.Approved
TicrynafenMinoxidil may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Minoxidil is combined with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Minoxidil is combined with Tizanidine.Approved
TolazolineMinoxidil may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Minoxidil is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypotensive activities of Minoxidil.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Minoxidil.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Minoxidil.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Minoxidil.Approved
TravoprostTravoprost may increase the hypotensive activities of Minoxidil.Approved
TreprostinilMinoxidil may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Minoxidil is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Minoxidil is combined with Triamterene.Approved
TrichlormethiazideMinoxidil may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinMinoxidil may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanMinoxidil may increase the hypotensive activities of Trimethaphan.Approved
UdenafilUdenafil may increase the antihypertensive activities of Minoxidil.Approved, Investigational
UnoprostoneMinoxidil may increase the hypotensive activities of Unoprostone.Approved
Valproic AcidThe serum concentration of Minoxidil can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Minoxidil.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Minoxidil.Approved
VerapamilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Verapamil.Approved
VinpocetineMinoxidil may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineMinoxidil may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Minoxidil.Approved, Vet Approved
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Paul S. Uster, Yolanda P. Quinn, “Non-crystalline minoxidil composition, its production and application.” U.S. Patent US4828837, issued March, 1985.

US4828837
General References
  1. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B: A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007 Nov;57(5):767-74. Epub 2007 Aug 29. [PubMed:17761356 ]
External Links
ATC CodesD11AX01C02DC01
AHFS Codes
  • 24:08.20
  • 84:92.00
PDB EntriesNot Available
FDA labelDownload (145 KB)
MSDSDownload (73.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9945
Blood Brain Barrier+0.9496
Caco-2 permeable+0.7214
P-glycoprotein substrateSubstrate0.596
P-glycoprotein inhibitor INon-inhibitor0.8959
P-glycoprotein inhibitor IINon-inhibitor0.8453
Renal organic cation transporterNon-inhibitor0.5721
CYP450 2C9 substrateNon-substrate0.8761
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6099
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6999
Ames testAMES toxic0.5253
CarcinogenicityNon-carcinogens0.9006
BiodegradationNot ready biodegradable0.9616
Rat acute toxicity2.2308 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.678
hERG inhibition (predictor II)Inhibitor0.7016
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Johnson and johnson group consumer companies
  • Actavis mid atlantic llc
  • Bausch and lomb pharmaceuticals inc
  • Copley pharmaceutical inc
  • Hi tech pharmacal co inc
  • Novex pharma
  • Perrigo co
  • Sight pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Wockhardt eu operations (swiss) ag
  • Avacor products llc
  • L perrigo co
  • Perrigo new york inc
  • Harmony laboratories
  • Pharmacia and upjohn co
  • Quantum pharmics ltd
  • Mutual pharmaceutical co inc
  • Par pharmaceutical inc
  • Royce laboratories inc
  • Usl pharma inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
LiquidTopical20 mg
LiquidTopical2 g/100mL
LiquidTopical20 mg/mL
LiquidTopical2 %
Aerosol, foamTopical5 g/100g
SolutionTopical3 g/60mL
SolutionTopical2 g/100mL
SolutionTopical20 mg
SolutionTopical50 mg/mL
SolutionTopical20 mg/mL
SolutionTopical2 %
TabletOral10 mg
TabletOral2.5 mg
LiquidTopical50 mg/mL
Aerosol, foamTopical50 mg/g
TabletOral10 mg/1
TabletOral2.5 mg/1
Aerosol, foamTopical5 %
SolutionTopical.02 g/mL
SolutionTopical5 g/100mL
Prices
Unit descriptionCostUnit
Rogaine ex-str starter kit28.32USD kit
Minoxidil powder2.07USD g
Loniten 10 mg Tablet1.52USD tablet
Minoxidil 10 mg tablet1.32USD tablet
Minoxidil 2.5 mg tablet0.7USD tablet
Loniten 2.5 mg Tablet0.39USD tablet
Rogaine 5 % foam0.27USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6946120 No1999-04-202019-04-20Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point248 °CPhysProp
water solubility2200 mg/LMERCK INDEX (1996)
logP1.24HANSCH,C ET AL. (1995)
pKa4.61MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility19.9 mg/mLALOGPS
logP1.24ALOGPS
logP1.3ChemAxon
logS-1ALOGPS
pKa (Strongest Acidic)14.22ChemAxon
pKa (Strongest Basic)4.34ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.63 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity60.74 m3·mol-1ChemAxon
Polarizability21.93 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic nitrogen compounds
Sub ClassOrganonitrogen compounds
Direct ParentDialkylarylamines
Alternative Parents
Substituents
  • Dialkylarylamine
  • Aminopyrimidine
  • Imidolactam
  • Pyrimidine
  • Primary aromatic amine
  • Piperidine
  • Heteroaromatic compound
  • Azacycle
  • Organoheterocyclic compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Organic oxide
  • Hydrocarbon derivative
  • Primary amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Phosphatidylinositol-4,5-bisphosphate binding
Specific Function:
In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive vol...
Gene Name:
KCNJ1
Uniprot ID:
P48048
Molecular Weight:
44794.6 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kirsten R, Nelson K, Kirsten D, Heintz B: Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet. 1998 Jun;34(6):457-82. [PubMed:9646008 ]
  4. Evans JM, Allan AK, Davies SA, Dow JA: Sulphonylurea sensitivity and enriched expression implicate inward rectifier K+ channels in Drosophila melanogaster renal function. J Exp Biol. 2005 Oct;208(Pt 19):3771-83. [PubMed:16169954 ]
  5. Loffler-Walz C, Quast U: Binding of K(ATP) channel modulators in rat cardiac membranes. Br J Pharmacol. 1998 Apr;123(7):1395-402. [PubMed:9579735 ]
  6. Bray KM, Quast U: A specific binding site for K+ channel openers in rat aorta. J Biol Chem. 1992 Jun 15;267(17):11689-92. [PubMed:1601843 ]
  7. Black KL, Yin D, Konda BM, Wang X, Hu J, Ko MK, Bayan JA, Sacapano MR, Espinoza AJ, Ong JM, Irvin D, Shu Y: Different effects of KCa and KATP agonists on brain tumor permeability between syngeneic and allogeneic rat models. Brain Res. 2008 Aug 28;1227:198-206. doi: 10.1016/j.brainres.2008.06.046. Epub 2008 Jun 21. [PubMed:18602898 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Kurbel S, Kurbel B, Zanic-Matanic D: Minoxidil and male-pattern alopecia: a potential role for a local regulator of sebum secretion with vasoconstrictive effects? Med Hypotheses. 1999 Nov;53(5):402-6. [PubMed:10616041 ]
  2. Gaffar A, Scherl D, Afflitto J, Coleman EJ: The effect of triclosan on mediators of gingival inflammation. J Clin Periodontol. 1995 Jun;22(6):480-4. [PubMed:7560228 ]
  3. Michelet JF, Commo S, Billoni N, Mahe YF, Bernard BA: Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. 1997 Feb;108(2):205-9. [PubMed:9008235 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 21, 2017 02:41